Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008401 | 0.84 | HTT (0.50) | HTTKMT2AALDH1A1MAPTMAPK14 | |
| SCHEMBL1819331 | 0.81 | HTT (0.60) | HTTKMT2AALDH1A1MAPTMAPK14 | |
| SCHEMBL3864013 | 0.75 | C5AR1 (0.40) | ALDH1A1MAPTRIPK2 | |
| SCHEMBL23398744 | 0.72 | MAPK14 (0.41) | HTTKMT2AALDH1A1MAPTMAPK14 | |
| SCHEMBL23402846 | 0.72 | MAPK14 (0.41) | HTTKMT2AALDH1A1MAPTMAPK14 | |
| SCHEMBL5007710 | 0.71 | BRAF (0.46) | HTTKMT2AALDH1A1MAPTMAPK14 | |
| SCHEMBL23402859 | 0.71 | MAPK14 (0.40) | HTTKMT2AALDH1A1MAPTMAPK14 | |
| SCHEMBL23401990 | 0.71 | MAPK14 (0.40) | HTTKMT2AALDH1A1MAPTMAPK14 | |
| SCHEMBL1013289 | 0.69 | ALDH1A1 (0.56) | HTTKMT2AALDH1A1MAPTMAPK14 | |
| SCHEMBL1815226 | 0.68 | MAPK14 (0.55) | HTTKMT2AALDH1A1MAPTMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1567517-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004050651-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050651-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | HTT 1948/4885KMT2A 4310/4885ALDH1A1 1326/4885 |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | HTT 1948/4885KMT2A 4310/4885ALDH1A1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.